AIM VACCINE (06660): Iterative process efficiently completes phase III clinical on-site work for human diploid rabies vaccine.

AIM VACCINE (06660) announces that the group has successfully completed the on-site work of the Phase III clinical trial of the double-dose rabies vaccine developed using an iterative process. This marks the official entry of the vaccine into a new phase, laying a solid foundation for future commercialization. This product is an upgraded double-dose rabies vaccine with significantly higher efficacy. It represents a major iteration and upgrade in the global rabies vaccine technology field. Animal experiments have shown that the group's double-dose rabies vaccine can produce a high level of protective antibodies after immunization. Under the same dosage conditions, the efficacy of the group's double-dose rabies vaccine is significantly higher than that of the double-dose rabies vaccine currently on the market. Rabies is the deadliest disease in the world, with a mortality rate close to 100% once contracted. Currently, there is a lack of effective treatment for rabies in clinical practice, making prevention crucial after exposure. The main preventive measure is to vaccinate with a human rabies vaccine. Compared to traditional Vero cell rabies vaccines, the human double-dose rabies vaccine uses human diploid cells instead of Vero cells. These cells are of human origin, providing a natural safety advantage. The human double-dose rabies vaccine currently on the market is priced 3 to 5 times higher than Vero cell rabies vaccines and offers higher product added value. Compared to traditional first-generation human double-dose rabies vaccines, the group's developed iterative process high-efficiency human double-dose rabies vaccine has overcome the technical bottleneck of low virus titers and low yields in traditional processes. Optimization and innovation have been carried out in the purification process, leading to significant improvements in product quality and safety. This not only demonstrates the company's R&D strength but also represents a significant breakthrough in the field of high-efficiency rabies vaccine processes globally. China is the world's largest rabies vaccine market, with estimates predicting it will reach 14.8 billion by 2030 due to product updates, iterations, and increased rabies vaccine coverage. The group's developed product can be administered through the "five-needle method," the "simple four-needle method," or the "2-1-1 four-needle method," offering greater flexibility and convenience compared to traditional rabies vaccine injection methods. According to the "Rabies Exposure Prevention and Disposal Work Norms (2023 Edition)" formulated by the National Health Commission and the Chinese Center for Disease Control and Prevention, rabies vaccine clinics must be equipped with at least two different types of rabies vaccines. With its iterative technical advantages and flexible injection methods, the group's product is expected to become the preferred choice for vaccine administration institutions. The group has established a state-of-the-art production workshop for the iterative process high-efficiency human double-dose rabies vaccine that meets international standards and has completed the production of samples for commercial-scale Phase III clinical trials, demonstrating the ability to produce the product on a large scale. The human double-dose rabies vaccine is recommended by the World Health Organization as the gold standard for rabies vaccines and is widely used in several developed countries. As the world's second largest supplier of rabies vaccines, the group is committed to leading the in-depth technical iteration and upgrade of global rabies vaccines, providing the market with a series of rabies vaccine products of better quality and higher safety levels, further solidifying the company's leading position in the global rabies vaccine field and driving sustainable development. The approval of this product in the future will enrich the company's product structure, synergize with the existing rabies vaccine series, enhance core competitiveness, contribute additional revenue as part of global expansion efforts, strengthen the company's market position, and provide new impetus for the company's continued steady development.